The incidence of heterogeneity of HER2 status in breast cancer (as determined by ISH) is variably estimated at up to 11%, and this may underlie some of the cases of “genuine” HER2 status change, reflecting outgrowth of an undetected clone [19]. Here, ERBB2 is linked to breast carcinoma.